Margaret H Chang, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uveitis | 3 | 2024 | 396 | 1.350 |
Why?
|
Macrophage Activation Syndrome | 7 | 2024 | 124 | 0.980 |
Why?
|
Synovial Membrane | 3 | 2024 | 532 | 0.910 |
Why?
|
Arthritis, Rheumatoid | 5 | 2024 | 3753 | 0.760 |
Why?
|
Methotrexate | 2 | 2024 | 1718 | 0.700 |
Why?
|
Arthritis | 2 | 2024 | 681 | 0.590 |
Why?
|
Feasibility Studies | 1 | 2024 | 5250 | 0.440 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2022 | 269 | 0.440 |
Why?
|
Autoantibodies | 2 | 2023 | 2119 | 0.370 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 4 | 2023 | 536 | 0.350 |
Why?
|
Coronary Aneurysm | 2 | 2023 | 233 | 0.340 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2023 | 4574 | 0.330 |
Why?
|
Macrophage Colony-Stimulating Factor | 2 | 2009 | 186 | 0.330 |
Why?
|
Type C Phospholipases | 1 | 2009 | 286 | 0.310 |
Why?
|
Arthritis, Experimental | 2 | 2021 | 291 | 0.280 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2023 | 619 | 0.280 |
Why?
|
Receptors, Adrenergic, beta | 1 | 2005 | 242 | 0.240 |
Why?
|
Uveitis, Anterior | 1 | 2024 | 101 | 0.230 |
Why?
|
Herpesvirus 8, Human | 1 | 2005 | 255 | 0.220 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 481 | 0.220 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2009 | 2864 | 0.210 |
Why?
|
Immediate-Early Proteins | 1 | 2005 | 444 | 0.210 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 2 | 2021 | 299 | 0.200 |
Why?
|
Joints | 1 | 2024 | 322 | 0.200 |
Why?
|
Galectin 1 | 2 | 2015 | 128 | 0.190 |
Why?
|
Glucose | 2 | 2009 | 4342 | 0.180 |
Why?
|
Prevotella | 1 | 2020 | 80 | 0.170 |
Why?
|
Child | 15 | 2024 | 80152 | 0.170 |
Why?
|
Interferon Type I | 1 | 2023 | 557 | 0.170 |
Why?
|
Synovial Fluid | 1 | 2021 | 393 | 0.160 |
Why?
|
Comparative Effectiveness Research | 1 | 2024 | 709 | 0.160 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2021 | 3092 | 0.160 |
Why?
|
Eosinophilia | 1 | 2023 | 557 | 0.150 |
Why?
|
Glycosylation | 2 | 2019 | 1095 | 0.150 |
Why?
|
Viral Proteins | 1 | 2005 | 1798 | 0.150 |
Why?
|
Cell Polarity | 1 | 2021 | 638 | 0.150 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2019 | 1651 | 0.150 |
Why?
|
Adenosine Deaminase | 1 | 2019 | 250 | 0.140 |
Why?
|
Macrophages | 2 | 2009 | 5753 | 0.140 |
Why?
|
Immunologic Memory | 1 | 2024 | 1361 | 0.140 |
Why?
|
Antigen-Antibody Complex | 1 | 2019 | 509 | 0.140 |
Why?
|
Consensus | 2 | 2024 | 3134 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 548 | 0.140 |
Why?
|
Physical Examination | 1 | 2022 | 1255 | 0.130 |
Why?
|
Dendritic Cells | 3 | 2015 | 2726 | 0.130 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2020 | 668 | 0.130 |
Why?
|
Trans-Activators | 1 | 2005 | 2846 | 0.130 |
Why?
|
Interleukin-1beta | 1 | 2021 | 1002 | 0.130 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2219 | 0.120 |
Why?
|
Antirheumatic Agents | 1 | 2024 | 1369 | 0.120 |
Why?
|
Antigens, Bacterial | 1 | 2020 | 1140 | 0.120 |
Why?
|
Protein Kinase C | 2 | 2009 | 1202 | 0.120 |
Why?
|
Biological Products | 1 | 2023 | 915 | 0.110 |
Why?
|
Pilot Projects | 2 | 2024 | 8642 | 0.110 |
Why?
|
Th17 Cells | 1 | 2020 | 794 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2017 | 726 | 0.110 |
Why?
|
Lung Diseases | 1 | 2023 | 1910 | 0.100 |
Why?
|
Mice, Knockout | 4 | 2021 | 14392 | 0.100 |
Why?
|
Humans | 27 | 2024 | 761208 | 0.100 |
Why?
|
Immunoglobulin G | 3 | 2020 | 4537 | 0.100 |
Why?
|
T-Lymphocytes | 2 | 2021 | 10203 | 0.100 |
Why?
|
Megakaryocytes | 1 | 2017 | 566 | 0.100 |
Why?
|
Animals | 11 | 2024 | 168079 | 0.100 |
Why?
|
Adolescent | 8 | 2024 | 88298 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1878 | 0.100 |
Why?
|
Wnt1 Protein | 1 | 2009 | 122 | 0.080 |
Why?
|
Glucose Transporter Type 1 | 1 | 2009 | 185 | 0.080 |
Why?
|
Registries | 1 | 2024 | 8247 | 0.080 |
Why?
|
Mice | 8 | 2022 | 81326 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2024 | 4673 | 0.070 |
Why?
|
Disease Progression | 1 | 2024 | 13511 | 0.070 |
Why?
|
Interleukin-1 | 2 | 2023 | 1250 | 0.070 |
Why?
|
Lipoproteins, LDL | 1 | 2009 | 643 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2022 | 14610 | 0.070 |
Why?
|
Cell Movement | 2 | 2015 | 5195 | 0.060 |
Why?
|
Child, Preschool | 6 | 2024 | 42224 | 0.060 |
Why?
|
Calcium-Binding Proteins | 1 | 2009 | 1067 | 0.060 |
Why?
|
Virus Activation | 1 | 2005 | 319 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2009 | 2455 | 0.050 |
Why?
|
Norepinephrine | 1 | 2005 | 897 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 185 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 1404 | 0.050 |
Why?
|
Endothelial Cells | 1 | 2015 | 3551 | 0.050 |
Why?
|
Cell Survival | 2 | 2009 | 5778 | 0.050 |
Why?
|
Male | 11 | 2024 | 360693 | 0.050 |
Why?
|
Epinephrine | 1 | 2005 | 791 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2019 | 18220 | 0.050 |
Why?
|
Signal Transduction | 4 | 2009 | 23416 | 0.050 |
Why?
|
Inflammation | 1 | 2022 | 10759 | 0.050 |
Why?
|
HLA-DR Antigens | 1 | 2023 | 606 | 0.050 |
Why?
|
Actins | 1 | 2009 | 2046 | 0.050 |
Why?
|
Female | 11 | 2024 | 392544 | 0.050 |
Why?
|
Pain Measurement | 2 | 2022 | 3549 | 0.050 |
Why?
|
Cell Line | 3 | 2015 | 15545 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2009 | 2426 | 0.040 |
Why?
|
Prospective Studies | 1 | 2024 | 54435 | 0.040 |
Why?
|
RANK Ligand | 1 | 2021 | 318 | 0.040 |
Why?
|
Infant | 4 | 2024 | 36169 | 0.040 |
Why?
|
Chemokine CXCL9 | 1 | 2019 | 135 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2022 | 3821 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 2871 | 0.040 |
Why?
|
Proteomics | 2 | 2023 | 3840 | 0.040 |
Why?
|
Adoptive Transfer | 1 | 2021 | 823 | 0.040 |
Why?
|
Blood Sedimentation | 1 | 2019 | 235 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 425 | 0.040 |
Why?
|
Cell Differentiation | 2 | 2021 | 11509 | 0.040 |
Why?
|
Interleukin-18 | 1 | 2019 | 250 | 0.040 |
Why?
|
Osteoclasts | 1 | 2021 | 711 | 0.040 |
Why?
|
Interleukin-17 | 1 | 2023 | 913 | 0.040 |
Why?
|
NF-E2 Transcription Factor, p45 Subunit | 1 | 2017 | 53 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2023 | 976 | 0.040 |
Why?
|
Ferritins | 1 | 2019 | 596 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2024 | 80674 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2020 | 979 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2021 | 1867 | 0.030 |
Why?
|
Dermatomyositis | 1 | 2019 | 258 | 0.030 |
Why?
|
Cytokines | 2 | 2023 | 7386 | 0.030 |
Why?
|
Th1 Cells | 1 | 2021 | 1042 | 0.030 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2017 | 284 | 0.030 |
Why?
|
Interleukin-6 | 2 | 2020 | 3210 | 0.030 |
Why?
|
Fever | 1 | 2023 | 1618 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2415 | 0.030 |
Why?
|
Focal Adhesion Kinase 2 | 1 | 2015 | 87 | 0.030 |
Why?
|
Adult | 4 | 2022 | 221119 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2020 | 1176 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2022 | 64681 | 0.030 |
Why?
|
Osteogenesis | 1 | 2021 | 1273 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2005 | 5773 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2009 | 18926 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2011 | 0.030 |
Why?
|
MicroRNAs | 1 | 2009 | 3758 | 0.030 |
Why?
|
Knee Joint | 1 | 2021 | 1678 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 6199 | 0.030 |
Why?
|
Reference Values | 1 | 2019 | 4921 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2009 | 7851 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1725 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2022 | 3571 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2009 | 22127 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2451 | 0.020 |
Why?
|
Mast Cells | 1 | 2017 | 1392 | 0.020 |
Why?
|
Matrix Metalloproteinase 10 | 1 | 2009 | 11 | 0.020 |
Why?
|
Matrix Metalloproteinase 12 | 1 | 2009 | 44 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2023 | 4744 | 0.020 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2009 | 92 | 0.020 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2009 | 153 | 0.020 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2009 | 145 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 4372 | 0.020 |
Why?
|
Deoxyglucose | 1 | 2009 | 333 | 0.020 |
Why?
|
Lymphedema | 1 | 2015 | 523 | 0.020 |
Why?
|
Ion Transport | 1 | 2009 | 319 | 0.020 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2009 | 332 | 0.020 |
Why?
|
bcl-X Protein | 1 | 2009 | 410 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2015 | 1720 | 0.020 |
Why?
|
Crohn Disease | 1 | 2020 | 2278 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4384 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2019 | 2157 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3691 | 0.020 |
Why?
|
Risk Factors | 2 | 2024 | 74239 | 0.020 |
Why?
|
Fibroblasts | 1 | 2017 | 4137 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2024 | 15841 | 0.020 |
Why?
|
Pain | 1 | 2021 | 5072 | 0.020 |
Why?
|
Tyrosine | 1 | 2009 | 1422 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 21365 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2009 | 1168 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14675 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2009 | 12747 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3808 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22174 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12976 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4567 | 0.010 |
Why?
|
Blotting, Western | 1 | 2009 | 5032 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2009 | 2199 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7400 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3777 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14025 | 0.010 |
Why?
|
Phosphorylation | 1 | 2009 | 8300 | 0.010 |
Why?
|
Computational Biology | 1 | 2009 | 3499 | 0.010 |
Why?
|
Protein Binding | 1 | 2009 | 9297 | 0.010 |
Why?
|
Calcium | 1 | 2009 | 5719 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36415 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2009 | 11856 | 0.010 |
Why?
|